FDA approves Lilly and Boehringer’s Basaglar insulin glargine injection
However, the final approval of the new injection has been kept on hold until the end of the 30-month period in mid-2016, as per the Drug Price Competition
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
To determine the effectiveness of FlunisynTM ITS produced its own live influenza challenge agent derived from the recently circulating Influenza A/California/2009 (H1N1) virus. This challenge virus, manufactured in
The goal of the collaboration is to commercialize proprietary formulations of nature-identical synthetic astaxanthin products with pharmaceutical-grade purity that will provide improved oral bioavailability compared with other astaxanthin
Specifically, the nitric oxide-releasing technology was found to be effective against Acinetobacter baumannii, a gram-negative bacterium resistant to nearly all antibiotics, which causes pneumonia, urinary tract infection, and